塔利班在2026年2月停止了巴基斯坦的药品进口,造成短缺和更高的成本,尽管当地产量有所增长。 Taliban halted Pakistan medicine imports in Feb 2026, causing shortages and higher costs despite boosting local production.

阿富汗塔利班领导的政府于2026年2月终止了从巴基斯坦的进口,旨在打击假药和促进国内生产,从而扰乱了该国的药品供应。 Afghanistan’s Taliban-led government has disrupted the country’s medicine supply by ending imports from Pakistan in February 2026, aiming to combat counterfeit drugs and boost domestic production. 突然的转变造成了短缺、价格暴涨以及供货商转向伊朗、印度和其他国家的交货时间更长,运输成本从6-7%提高到25-30%。 The abrupt shift has caused shortages, price hikes, and longer delivery times as suppliers turned to Iran, India, and other nations, increasing transport costs from 6–7% to 25–30%. 虽然国内制造业已扩大到600种药品,但高能源成本、有限的基础设施和对进口原料的依赖限制了产出。 While domestic manufacturing has expanded to 600 medicines, high energy costs, limited infrastructure, and reliance on imported raw materials restrict output. 医生面临调整处方的挑战,患者尽管有自给自足的长期目标,但费用较高,治疗延误也较高。 Doctors face challenges adjusting prescriptions, and patients experience higher costs and treatment delays, despite long-term goals of self-sufficiency.